Massachusetts General Hospital

SIP Brain Health Innovation Olympics Awards Global Student Teams in Intergenerational Competition

Retrieved on: 
Wednesday, April 3, 2024
University, Harvard Medical School, Season, Innovation, Rotman School of Management, Entrepreneurship, Massachusetts General Hospital, Science, Dartmouth College, Sodexo, Senior, Student, Asian Institute of Management, Olympic Games, Hospital, SIP, Management

Participating students from colleges and universities around the world joined SIP's Brain Health Innovation Olympics challenge to create Brain Health Centers of Excellence.

Key Points: 
  • Participating students from colleges and universities around the world joined SIP's Brain Health Innovation Olympics challenge to create Brain Health Centers of Excellence.
  • Winning concepts include fully integrated solutions to deliver Brain Health Centers of Excellence in Senior Living Communities, Brain Health incubators and investment funds, workplace brain health programs, and increased caregiver support.
  • The 2nd Season of the Brain Health Innovation Olympics represents a significant step forward in advancing brain health initiatives globally.
  • For more information about Social Impact Partners and the Brain Health Innovation Olympics, please visit www.socialimpact.partners and join SIP's Global Brain Health and Longevity Initiative.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, JDRF, Kidney disease, Massachusetts General Hospital, Risk, Immunosuppression, Patient, Kidney transplantation, OLE, University, Tacrolimus, Glomerular filtration rate, Net, Investment, Society, Hospital, EGFR, Kidney, Safety, Pharmacokinetics, FACS, Annual general meeting, Pharmaceutical industry

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2023 operating and financial results and reviewed recent business highlights.

Key Points: 
  • In addition to our clinical development progress, tegoprubart was used for immunosuppression in historical kidney and heart pig-to-human xenotransplant procedures.
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man with end-stage kidney disease.
  • Results were presented at the American Society of Nephrology Kidney Week 2023 Annual Meeting held in Philadelphia, PA in November 2023.
  • General and administrative expenses were $12.7 million for the year ended December 31, 2023, compared to $12.7 million for the year ended December 31, 2022.

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Internal medicine, Boston Children's Hospital, Harvard Medical School, Swedish Orphan Biovitrum, Massachusetts General Hospital, Genzyme, Patient, SAN, Inflammation, Senior, Pediatrics, KIT, Hospital, Medicine, Management

SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.

Key Points: 
  • SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors.
  • Prior to this role, he served as the President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 to 2017.
  • at Harvard Medical School and completed residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children's Hospital.
  • “I am excited to join the exceptional team at Third Harmonic Bio in working to expand the treatment landscape for mast cell disorders.”

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

New Health Economic Analysis Presented at ACC Highlights the Acarix CADScor System's Cost-Effectiveness

Retrieved on: 
Monday, April 8, 2024
Faculty, Chest pain, Coronary artery disease, Massachusetts General Hospital, Health, Incidence, Risk, Patient, Anxiety, MD, Master of Science, Emergency department, American College, ED, Physician, ACC, CAD, Medical device

"This not only leads to increased healthcare costs but also results in the improper utilization of resources.

Key Points: 
  • "This not only leads to increased healthcare costs but also results in the improper utilization of resources.
  • Additionally, the incidence of missed cardiac events with the CADScor System was remarkably low, indicating that the anticipated economic benefit did not compromise clinical outcomes.
  • "This study reaffirms the comprehensive value proposition of the CADScor System for patients, physicians, and payors alike.
  • Physicians can easily and quickly determine the next steps, facilitating cost efficiencies for healthcare systems and payors by reducing unnecessary testing."

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Retrieved on: 
Thursday, March 21, 2024
Organ transplantation, Kidney disease, University of Minnesota, Massachusetts General Hospital, Risk, Patient, Immunosuppression, Research, Kidney transplantation, University, Kidney, Hope, Tacrolimus, Doctor of Philosophy, MD, Person, Hospital, Heart, Immune system, Calcineurin, Division, CD40L, Dentistry

IRVINE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human. The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.

Key Points: 
  • The procedure was completed on March 16, 2024, at Massachusetts General Hospital on a 62-year-old man living with end-stage kidney disease.
  • “Eledon has now participated in both heart and kidney xenotransplant procedures, further demonstrating tegoprubart’s broad potential in transplant.
  • Tegoprubart has been observed to be safe and well-tolerated in multiple studies and in multiple indications, including for the prevention of rejection following kidney transplantation.
  • In parallel, Eledon is running two global clinical studies evaluating tegoprubart for the prevention of organ rejection in persons receiving a de novo kidney transplant.

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Wednesday, March 20, 2024
Research, Harvard Medical School, Massachusetts General Hospital, Nicotine, Smoker, NIH, Society, Smoking, Safety, Bangladesh Technical Education Board, Annual general meeting, Tobacco

March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.

Key Points: 
  • March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.
  • Data collected include trial participants’ experiences, such as cravings and withdrawal symptoms, personal impact on overall health, and opinions on future use.
  • ORCA-V1 evaluated the effectiveness and safety of cytisinicline in users of nicotine e-cigarettes who wanted to quit vaping.
  • The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.